Immunobiotics beneficially modulate TLR4 signaling triggered by lipopolysaccharide and reduce hepatic steatosis in vitro by Kanmani, Paulraj et al.
Research Article
Immunobiotics Beneficially Modulate TLR4 Signaling
Triggered by Lipopolysaccharide and Reduce Hepatic
Steatosis In Vitro
Paulraj Kanmani ,1 AbuZar Ansari,1 Julio Villena,2 and Hojun Kim 1
1Department of Rehabilitation Medicine of Korean Medicine, Dongguk University, Goyang, Republic of Korea
2Laboratory of Immunobiotechnology, Reference Centre for Lactobacilli (CERELA-CONICET), Tucuman, Argentina
Correspondence should be addressed to Hojun Kim; kimklar@empas.com
Received 30 August 2018; Revised 2 January 2019; Accepted 30 January 2019; Published 14 March 2019
Academic Editor: Senthamil R. Selvan
Copyright © 2019 Paulraj Kanmani et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Hepatic inflammation and injury may result from the translocation of pathological bacteria and their proinflammatory mediators.
Probiotics attenuate hepatic diseases related to inflammation by exhibiting immunoregulatory effects. Therefore, this study was
conducted to evaluate lipid reduction and immunoregulatory potentials of probiotic bacteria in vitro. HepG2 cells treated with
total cellular fluid (TCF) of LABs reduced lipid accumulation. Moreover, cells responded to lipopolysaccharide (LPS) by
producing higher levels of IL-6, IL-8, MCP-1, and TNF-α. TCF of LABs treatment showed remarkably diminished levels of the
expression of these cytokines via modulation of the expression of TLR-negative regulators, as well as MAPK and NF-κB
pathways. Moreover, heat-killed LABs were able to diminish TGF-β, IL-1β, and IL-6 and to increase IL-10 and TLR4 levels in
THP-1 cells. LABs also decreased the protein level of TNF-α. These results demonstrated that immunobiotics exhibit potent
immunoregulatory activity and may be used as effective therapeutic agents to alleviate inflammatory response.
1. Introduction
Because of their various functional capabilities, probiotics
and their applications in real-world food and feed industries,
as well as in clinical and medical fields, have increased over
the last two decades. Probiotics are live beneficial microor-
ganisms that confer health-promoting effects to the host
when consumed in adequate amounts [1]. Most probiotics
are lactic acid bacteria (LABs), which are a group of bacterial
strains primarily found in fermented products and the guts of
mammals. Lactobacillus sp. and Bifidobacteria are promising
LABs that are increasingly recognized and utilized by
humans as probiotic bacteria. A bacterial strain that has
potent immunoregulatory functions is defined as immuno-
biotic [2]. Accordingly, the potential health-promoting
effects of these strains have been extensively studied for use
in the treatment of various diseases, including liver diseases.
The results of these investigations have shown that these
bacteria can withstand gastrointestinal conditions and exert
several beneficial effects, including immunomodulation,
anti-obesity, strengthening of gut barrier function, antican-
cer, promotion of dietary uptake, prevention of intestinal
inflammation, and increasing antagonism against invaders
[3–6]. Several mechanisms have been postulated to be
responsible for these beneficial effects of probiotics; however,
they are mainly achieved through the regulation of the intes-
tinal immune system and maintenance of gut microflora
homeostasis [7].
The liver is a primary regulator of several physiological
processes and many diseases, including liver inflammation,
hepatic steatosis, fibrosis, cirrhosis, hepatocellular carci-
noma, and hepatitis that are known to affect liver functions
[8]. However, the definite pathological mechanisms respon-
sible for the development of chronic liver diseases are not
yet known. Lipopolysaccharide (LPS) is an important cell
wall component of Gram-negative bacteria that has been
found to induce inflammatory response in infected cells
and lead to sepsis or endoxima and organ failure [8, 9].
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Increased circulation of bacterial LPS has been reported to
stimulate hepatocyte cells to produce higher amounts of pro-
inflammatory cytokines and fibrogenesis markers that induce
liver inflammation and progression of liver diseases [10, 11].
A significantly higher level of LPS was found in patients with
liver diseases [12, 13], indicating that the liver is not simply a
primary regulator of physiological functions but also a preem-
inent site or organ for the clearance of bacterial components
and its toxicity [14]. Lipopolysaccharide has been shown to
induce production of reactive oxygen species (ROS) and pro-
inflammatory cytokines/chemokines by hepatic cells through
interaction with pattern recognition receptors (PPRs) such as
Toll-like receptors (TLRs) [10, 15].
Toll-like receptor 4 (TLR4) is an active receptor for LPS.
Once it recognizes LPS, TLR4 promptly mediates inflamma-
tory signaling, which results in increased production of dif-
ferent inflammatory cytokines/chemokines in the inflamed
site [15]. TLR4 can be expressed by most liver cell types
and actively responds to LPS by producing an array of proin-
flammatory cytokines in vivo [10]. Many studies have con-
firmed the pathogenic role of TLR4/LPS signaling in the
development of alcoholic and nonalcoholic liver diseases,
hepatocellular carcinoma, hepatitis B and C, and primary bil-
iary cirrhosis [15]. An in vivo study showed that LPS signal-
ing induced hepatic fibrogenesis in a mouse model that was
found to be less susceptible to the development of hepatic
fibrogenesis when deficient for TLR4 [16]. TLR4/LPS signal-
ing induces hepatic fibrogenesis through the activation of
Kupffer and Hepatic stellate cells to produce higher levels
of profibrogenic cytokines (TGF-β), chemokines (CCL2,
CCL3, and CCL4), and adhesion molecules (ICAM-1 and
VCAM-1) [10].
Alcoholic and nonalcoholic liver diseases are closely
associated with changes in gut microbiota composition.
Administration of probiotics has been shown to ameliorate
the progression of liver diseases by modulating the host bac-
terial community [17, 18]. In addition, probiotics were able
to suppress LPS-induced hepatic injury in a mouse model
by maintaining intestinal barrier function [19]. Probiotics
may cause these positive intestinal and hepatic effects via dif-
ferent mechanisms that include providing substrates for
short-chain fatty acid (SCFA) production and facilitating
the bioavailability of bile acids [20]. Another in vivo study
showed that treatment with probiotics (VSL#3) improved
the development of liver steatosis in ob/ob mice [21]. More-
over, the clinical importance of these (VSL#3) probiotic
strains was confirmed in a cohort of patients with liver dis-
eases [22]. These studies confirmed the beneficial activity of
probiotics in the prevention of liver diseases in vivo. Indeed,
the beneficial effects of probiotics are strain-specific and their
functional properties; therefore, the screening and selection
of most active strains with potent probiotic effects are very
important to achieving target therapeutic effects. Most stud-
ies have used in vivo models to evaluate the probiotic effects,
while there have been fewer attempts in vitro, and no clear
mechanisms explored for the probiotic actions in vivo and
in vitro have been identified. In our previous study, we used
hepatoma HepG2 cells to screen potent probiotic strains
and analyze their immunoregulatory effects [23]. In this
study, we selected three different lactic acid bacteria based
on their antimicrobial activity, reduction of fat accumulation,
and bile and acid stability. HepG2 cells were used to screen
the most active probiotic strains with antihepatic steatosis
and immunomodulatory capabilities, as well as to study the
molecular mechanisms involved in the immunoregulatory
activity of probiotics.
2. Materials and Methods
2.1. Cell Culture. Human hepatoma HepG2 cells from the
Korean cell line bank (Seoul, South Korea) were purchased
and maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco, USA). For the experiments, cells were cul-
tured in DMEM/high-glucose medium (Gibco™) containing
10% fetal bovine serum (FBS, Gibco, USA) and 1% penicil-
lin/streptomycin at 37°C under 5% CO2. The media was
changed at every two-day interval for 5-6 days. In addition,
the human monocytic cell line (THP-1) was purchased from
the Korean cell line bank and maintained in RPMI-1640
medium (Gyeongsangbuk-do, South Korea) until used for a
coculture investigation.
2.2. Bacterial Strains. Three different lactic acid bacteria
(LABs) were isolated from Korean fermented foods. The
phenotypical and genotypical characterizations were per-
formed with appropriate techniques and identified as
Weissella cibaria strain DUHJ2, Lactobacillus sakei, and L.
plantarum strain DUHJ2 (hereafter referred to as WCI,
LSA, and LPL, respectively). The strains were cultured in
MRS broth at 37°C for 19 h, after which they were centri-
fuged, washed once with DPBS, and subsequently mixed with
DMEM at appropriate concentrations, then stored at -4°C
until further investigation.
2.3. Induction of Hepatic Steatosis (HS) and Differentiation of
THP-1 Cells. Hepatic steatosis was induced as described pre-
viously [23]. Briefly, hepatoma HepG2 cells were cultured
(5 × 104 cells/ml) in 12-well type I collagen-coated plates
(SPL Life Sciences Co. Ltd., Gyeonggi-do, South Korea) at
37°C for 3-4 days. The confluent cells were then incubated
with DMEM supplemented with 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin, 1% bovine serum albumin
(BSA), and 1mM free fatty acid [FFA (2 : 1 of oleic acid
(0.66mM) and palmitic acid (0.33mM) prepared in 100%
isopropanol)] for 24 h. Finally, the incubated cells were
washed with distilled phosphate-buffered saline (DPBS) until
further analysis.
To differentiate THP-1 cells, they were cultured in
RPMI-1640 supplemented with 1% FBS, 1% penicillin/strep-
tomycin, and 0.05mMmercaptoethanol at 37°C for 5-6 days.
The cells were then incubated with differentiation medium
(RPMI 1640 media with 50 ng/ml of PMA (Phorbol
12-Myrisate 13 Acetate)) for 48 h to induce conversion into
macrophage-like cells. Finally, differentiation medium was
replaced with fresh RPMI medium and subsequently incu-
bated at 37°C for 24 h, after which the differentiated cells
were used to prepare CFS of LAB strains and to coculture
with HepG2 cells.
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2.4. Preparation of Total Cellular Fluid (TCF) of LAB Strains.
The total cellular fluid of LABs was prepared as previously
described [23]. Briefly, differentiated THP-1 cells were cul-
tured (1 × 106 cells/well) in 6-well type I collagen-coated
plates (SPL Life Sciences Co. Ltd., Gyeonggi-do, South
Korea) and incubated with LAB strains (5 × 107 cells/well)
in RPMI media. After 24 h of incubation, the total cellular
fluids (TCFs) were transferred to fresh tubes, centrifuged,
and filter sterilized to remove cellular contents, after which
they were stored at -4°C for further stimulation studies.
The cytotoxicity of LAB strains and their TCFs was deter-
mined in hepatoma HepG2 cells using a cell viability, pro-
liferation, and cytotoxicity assay kit (EZ-CYTOX, DOGEN
Bio Co. Ltd.).
2.5. Reduction of Hepatic Steatosis. To evaluate the reduction
in hepatic steatosis, HepG2 cells were cultured (3 × 104
cells/ml) in 12-well collagen-coated plates at 37°C for 3 days,
then incubated with TCF (25μl and 50μl/ml) of different
LABs for 48h after treatment with 1mM of FFA for 24h.
The cells were then washed with DPBS and fixed with forma-
lin (10%) at room temperature (RT) for 5 minutes, after
which they were fixed with fresh formalin (10%) at RT for
1 h and subsequently washed with isopropanol (60%). The
completely dried plates were then stained with Oil Red O
(ORO) solution (0.5%) for 10 minutes at RT, washed four
times with deionized water (DW), and observed under a
microscope (Leica DMI 6000B, Wetzlar, Germany). To
quantify the amount of fat that accumulated in the cells,
1ml of isopropanol (100%) was added to each well and
allowed to stand for 5 minutes at RT, after which absorbance
was read at 520 nm using a microplate reader (SpectraMax
Plus 384, San Jose, CA, USA).
2.6. TCF of LABs Ameliorates LPS-Induced Inflammatory
Response in HepG2 Cells. HepG2 cells were cultured
(3 × 104 cells/ml) in 12-well plates at 37°C under 5% CO2.
Once fully confluent, cells were stimulated with 50μl TCF
of LABs for 48h before and after treatment with FFA for
24 h. The stimulated cells were then washed with DMEM
medium and poststimulated with 1μg/ml of LPS (lipopoly-
saccharide from E. coli O55.B5, Sigma-Aldrich, USA) for 3
and 12h. Finally, the mRNA levels of proinflammatory
cytokines/chemokines (IL-6, IL-8, MCP-1, and TNF-α) were
analyzed by RT-PCR.
2.7. Coculture Study. To determine the immunomodulatory
activity of LABs, HepG2 cells (3 5 × 104 cells/well) were cul-
tured in the upper chamber of transwell culture inserts
(transparent PTFE membrane-coated collagen, 0.4μm pore
size) (Transwell-COL, Corning Inc., NY, USA) at 37°C under
5% CO2. After 5-6 days, the confluent cells were cocultured
with macrophage-like THP-1 cells and then cultured in
the lower chamber. The apical monolayer of HepG2 cells
(TEER value 486Ω cm2) was subsequently stimulated with
heat-killed LABs for 48 h, after which 1μg/ml of LPS was
added to the basolateral side and incubation was continued at
37°C for 12 h. The cellular fluid (CF) from both apical and
basolateral sides was collected in fresh tubes and stored
at -4°C to determine the amount of TNF-α production at
the protein level using a Human TNF-α Quantikine
Enzyme-Linked Immunosorbent Assay (ELISA) kit (R&D
System, MN, USA) according to the manufacturer’s instruc-
tions. In addition, RNA from THP-1 cells was extracted by
adding TRIzol, after which the expression of cytokines and
receptors (IL-10, TGF-β, IL-6, IL-1β, TLR2, and TLR4) was
analyzed by RT-PCR [23].
2.8. Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR). Total RNA from cells was extracted by adding
TRIzol. The extracted RNA was used to analyze the expres-
sion of different cytokines using RT-PCR as previously
described [23]. Primers used in this study were mentioned
in Supplementary Table 1.
2.9. Modulation of MAPK and NF-κB Pathways by TCF of
LABs in HepG2 Cells. Hepatoma HepG2 cells were cultured
(1 8 × 105 cells/dish) in dishes (60mm) at 37°C and 5%
CO2 for 5-6 days. Fully confluent HepG2 cells were then
stimulated with the TCF of LABs at 37°C under 5% CO2 for
48 h, then poststimulated with LPS (1μg/ml) for 0, 10, 30,
60, and 120min. The cells were subsequently washed with
DPBS and lysed by adding 200μl of CelLytic M cell lysis
reagent (Sigma-Aldrich, St. Louis, MO, USA), scraped,
and transferred to fresh Eppendorf tubes that were stored
at −70°C for blotting. The concentration of protein in the
lysed sample was analyzed using a bicinchoninic acid
(BCA) assay kit (Thermo Scientific, Pierce, Rockford, IL,
USA). Equal amounts of samples were then loaded into
10% SDS-polyacrylamide gels, after which the proteins were
separated by electrophoresis at a constant voltage and then
transferred onto nitrocellulose membranes (Trans-Blot
Turbo™, BioRad). The membranes were subsequently cut at
the desired part and incubated with blocking buffer prior to
incubationwith antibodies to the targeted proteins. The phos-
phorylation of p38 MAPK and p65 NF-κB degradation were
evaluated by incubating the membranes with MAPK Phos-
pho-p38α (T180/Y182) antibody (p-p38α, Cat. #MAB8691,
R&D Systems, MN, USA), NF-κB phospho-p65 (p-p65,
Cat. #9242), and β-actin antibody (Cat. #4970) (dilution:
1 : 1000) from Cell Signaling Technology (Beverly, MA,
USA) overnight at room temperature. Next, membranes
were washed with buffer and subsequently incubated with
goat anti-rabbit IgG-HRP polyclonal antibody (dilution:
1 : 5000) (AbFrontier, Cat. #LF-SA8002). After 2 h, the
membranes were washed with buffer and the protein bands
were analyzed by adding a mixture (1 : 1 ratio) of western blot
detection solution A and B (SUPEX, Neonex Co. Ltd., Post-
ech, South Korea). Finally, the area of the densitogram peak
was estimated using ImageJ software (National Institute of
Health, Bethesda, MD, USA).
2.10. Modulation of LPS-Induced TLR-Negative Regulator
Expression in HepG2 Cells. Both FFA-treated and FFA-
untreated HepG2 cells were stimulated with the TCF of LABs
at 37°C under 5% CO2 for 48 h. After washing with DMEM
medium, both cells were poststimulated with 1μg/ml of
LPS for 3 and 12h. Next, the cells were washed with DPBS,
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lysed, and scraped by adding a TRIzol reagent, after which
the transferred samples were stored at −4°C to extract the
RNA. Finally, the mRNA levels of TLR-negative regulators
(A20, SIGIRR, Tollip, and IRAKM1) were analyzed by
RT-PCR.
2.11. Statistical Analysis. Statistical analyses were performed
using the SPSS software package (SPSS 12.0, SPSS Inc.,
Chicago, IL, USA). One-way analysis of variance (ANOVA)
was conducted, and the significance of each mean value was
determined by Tukey’s and Duncan’s multiple range tests
with a p < 0 05 considered to indicate significance.
3. Results
3.1. LABs Reduce Hepatic Steatosis In Vitro. In this study, we
used three different LAB strains (Weissella cibaria strain
DUHJ2, Lactobacillus sakei, and L. plantarum strain DUHJ2)
that were isolated from Korean fermented foods. The isolated
strains and their TCF did not affect the growth and prolifer-
ation of HepG2 cells and retained cells alive, similar to the
control. In addition, we analyzed whether the TCF of LABs
decreased the induction of hepatic steatosis in vitro using
HepG2 cells. As shown in Figure 1, the TCF of LABs reduced
FFA-induced hepatic steatosis by decreasing the accumula-
tion of lipids in HepG2 cells. However, strain- and TCF
level-dependent variations were observed in the reductions.
Specifically, a higher amount of TCF (50μl) showed better
reduction than lower amounts (25μl). Among LABs, the
TCF of LPL led to a significant decrease in lipid accumulation
(more than 18%) compared with LPS, followed by the TCF of
WCI and LSA, respectively.
3.2. LABs Attenuate LPS-Induced Inflammatory Response in
HepG2 Cells. We next analyzed whether the TCF of LABs
dampens inflammatory cytokine production in vitro. For this
analysis, both FFA-treated and FFA-untreated HepG2 cells
were prestimulated with the TCF of LABs, followed by
stimulation with LPS for 3 and 12 h. The results of RT-PCR
are shown in Figure 2. Treatment with LABs significantly
decreased the expression of inflammatory cytokine/-
chemokines in HepG2 cells. However, these reductions var-
ied with time, cells, and strains. At 3 h, LPS induced the
expression of all cytokines/chemokines in both FFA-treated
and FFA-untreated HepG2 cells. Moreover, FFA-treated cells
stimulated with the TCF of WCI and LPL showed downreg-
ulated mRNA levels of IL-6, IL-8, MCP-1, and TNF-α, while
the TCF of LSA failed to suppress the FFA-treated cells to
lower levels of IL-8 and MCP-1. The TCF of LABs exhibited
different patterns of inhibition in FFA-untreated cells com-
pared to FFA-treated cells. At 12h, the TCF of all LABs was
able to decrease the expression of IL-6 in FFA-treated cells,
but not in FFA-untreated cells (except for LPL). The levels
of IL-8 and MCP-1 were also significantly reduced by TCF
of all LABs except WCI in FFA-untreated cells, whereas
FFA-treated cells responded differentially to the TCF of LABs
(Figure 2). Moreover, the TCF of WCI and LPL stimulations
decreased the expression of TNF-α in both cell types, while
the TCF of LSA failed to reduce TNF-α in FFA-treated
cells. These results indicate that both FFA-treated and
FFA-untreated cells were highly responsive to the TCF of
LABs, showing different patterns of cytokine expression
after stimulation for different times.
3.3. LAB Strains Reduce Production of TNF-α in a Coculture
Model. To determine if LABs suppress THP-1 cells indirectly
through the influence of HepG2 cells in vitro, we cocultured
hepatomaHepG2 cells with THP-1 cells and stimulated them
with heat-killed LABs followed by LPS treatment for 12 h. As
shown in Figure 3, ELISA revealed that all LAB strains were
able to suppress THP-1 to produce higher amounts of
TNF-α. Strain LSA showed better activity than other strains.
In contrast, different patterns of TNF-α production were
observed inHepG2cells.Whencompared toTHP-1cells, hep-
atoma HepG2 cells showed a lower response to LAB strains.
3.4. Reduction of mRNA Level of Inflammatory and
Anti-Inflammatory Cytokines by LAB Strains in THP-1
Cells. We also investigated whether LAB strains modulate
the expression of inflammatory and anti-inflammatory cyto-
kines in THP-1 indirectly through HepG2 cells. The results
of RT-PCR showed that stimulation of cells with LABs
increased the mRNA level of IL-10, whereas it decreased
the expression of TGF-β (Figure 4). In addition, LPS induced




































































Figure 1: Lipid reduction potential of LABs in vitro. Free fatty
acid-treated HepG2 cells were incubated with total cellular fluid of
LABs (25μl and 50 μl/ml) and lipopolysaccharide (LPS) for 48 h,
and the amount of lipid reduced by total cellular fluid of LABs in
the cells was quantified using a spectrophotometer at 520 nm.
Different superscript letters indicate significant differences at the
0.05 level. Asterisks indicate significant differences (p < 0 05)
between the samples and LPS.
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LSA reduced this LPS-induced IL-6 expression indirectly.
The level of IL-1β was downregulated by all LABs, but not
by LPL. We also analyzed the expression of TLR receptors
in THP-1 cells. The expression of TLR2 was not significantly
altered by LAB strains, but all LABs showed significantly
increased expression of TLR4 in THP-1 cells. These results
confirm that isolated LAB strains could suppress cells not
only via direct contacts but also through indirect contacts
to produce lower levels of inflammatory cytokines in
response to LPS.
3.5. Modulation of MAPK and NF-κB Pathways. To deter-
mine if the TCFs of LABs modulate LPS-induced MAPK
and NF-κB pathways in vitro, we stimulated HepG2 cells
with the TCF of LABs for 48 h followed by LPS for 0, 30,
60, 90, and 120 minutes. Blotting analysis showed that LABs
were able to modulate LPS-induced p65 NF-κB and p38
MAPKs activation in HepG2 cells (Figure 5(a) and 5(b)).
However, these modulations varied remarkably in a time-
dependent manner. Stimulation of cells with LPS increased
the level of p65 NF-κB after stimulation for various lengths
of time, but these were reduced when cells were stimulated
with the TCF of LABs. The TCF of all LABS remarkably
decreased the levels of p-p65 compared to LPS after 30
minutes, and this continued for up to 120 minutes
(Figure 5(a), Supplementary Figure 1). Similarly, cells
stimulated with LPS increased the phosphorylation of p38
MAPKs in HepG2 cells; however, this LPS-induced p38
MAPK activation was inhibited when cells were treated
with the TCF of LABs (Figure 5(b)). Treatment with the
TCF of WCI led to reduction at all stimulation points, but
this difference relative to LPS was only significant (p < 0 05)
at 60 minutes. However, the TCF of LSA and LPL
diminished the level of p-p38 MAPK at all stimulation
points, but significantly lower levels were observed at 30
and 120 minutes, respectively. These results indicate that
the TCFs of LABs were able to decrease the expression
of inflammatory cytokine/chemokines by modulating the
MAPK and NF-κB pathways in HepG2 cells.
3.6. Regulation of TLR-Negative Regulator Expression by
LABs in HepG2 Cells. Several negative regulatory proteins
are known to play roles in the regulation of TLR signaling.

















































































































































































































Figure 2: Reduction of inflammatory response induced LPS in HepG2 cells. Both normal and free fatty acid-treated HepG2 cells were
stimulated with total cellular fluid (50 μl/ml) of LABs for 48 h, then poststimulated with LPS for 3 h and 12 h. The expression of
inflammatory cytokines (IL-6, CXCL8, CCL2, and TNF-α) was determined by real-time polymerase chain reaction (RT-PCR). HepG2 cell


























Figure 3: Reduction of TNF-α production in HepG2 cells and
THP-1 cells. In this coculture study, the apical side HepG2 cells
were stimulated with heat-killed LABs for 48 h, after which the
basolateral THP-1 cells were treated with LPS for 12 h. The
protein levels of TNF-α in both apical and basolateral sides were
determined. Cell treated with LPS was used as control. Different
superscript letters indicate significant differences at the 0.05 level.
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the expression of TLR-negative regulatory proteins in HepG2
cells under inflammatory conditions. We performed this
experiment in both FFA-treated and FFA-untreated HepG2
cells. The expression of TLR-negative regulators in
FFA-treated HepG2 cells at 3 and 12 h is shown in Figure 6.
Stimulation of FFA-treated cells with LPS increased the
expression of negative regulators at all stimulation hours.
These LPS-induced expressions were modulated when cells
were prestimulated with the TCF of LABs. However, these
modulationsvariedsignificantlydependingon the stimulation
hours. The TCF of all LABs decreased the expression of A20 at
3 h, while they increased A20 expression at 12 h compared to
LPS (Figure 6). However, the levels of Tollip and SIGIRRwere
diminished by the TCFs of all LABs at both 3 and 12h. Con-
versely, the mRNA level of IRAKM was significantly upregu-
lated at 12h after stimulation of cells with the TCF of LABs.
We also analyzed the expression of TLR-negative regula-
tors in FFA-untreated cells. When compared to FFA-treated
cells, FFA-untreated cells responded differentially to the TCF
of LABs (Figure 7). Stimulation of FFA-untreated cells with
CNT LPS WCI LSA LPL CNT LPS WCI LSA LPL
CNT LPS WCI LSA LPL
CNT LPS WCI LSA LPLCNT LPS WCI LSA LPL








































































































Figure 4: In vitro analysis of anti-inflammatory and inflammatory cytokines in THP-1 cells. In this coculture study, the apical side HepG2
cells were stimulated with heat-killed LABs for 48 h, after which basolateral THP-1 cells were treated with LPS for 12 h. The mRNA levels of
IL-10, TGF-β, IL-6, IL-1-β, TLR2, and TLR4 at mRNA were determined by RT-PCR. Cell treated with LPS alone was used as control.
Different superscript letters indicate significant differences at the 0.05 level.
6 Journal of Immunology Research
the TCF of LABs decreased the expression of A20 at both 3
and 12 h. However, the mRNA levels of Tollip and SIGIRR
were increased by the TCF of all LABs at 3 h, while they were
decreased at 12h. Conversely, the TCF of all LABs except
LSA showed significantly higher levels of IRAKM than LPS











































































Figure 5: Inhibition of p65 NF-κB and p38MAPK phosphorylation in HepG2 cells. HepG2 cells were prestimulated with total cellular fluid of
LABs for 48 h, then poststimulated with LPS for 0, 30, 60, 90, and 120min. The phosphorylation of p65 NF-κB and p38 MAPK was
determined by western blot analysis. Bar graphs represent the results of three independent experiments, and different superscript letters
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Figure 6: Modulation of the expression of TLR negative regulators by total cellular fluid of LABs in free fatty acid-treated HepG2 cells. HepG2
cells were prestimulated with total cellular fluid of LABs followed by stimulation with LPS for 3 h and 12 h. The expression of A20, SIGIRR,
Tollip, and IRAK-M1 was determined by RT-PCR. HepG2 cell treated with LPS was used as control. Different superscript letters indicate
significant differences at the 0.05 level.
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the TCFs of WCI and LPL at 3 h. These results confirm that
the TCFs of LABs were able to regulate TLR signaling by
modulation of the expression of TLR-negative regulators in
HepG2 cells.
4. Discussion
This study shows that the TCFs of LABs were able to dimin-
ish hepatic steatosis by reducing the accumulation of lipids,
as well as to attenuate bacterial LPS-induced inflammatory
response in hepatoma HepG2 cells, which is a well-character-
ized, transformed cell line model that has been extensively
used to analyze the beneficial effects of several components
and bacterial strains on hepatic functions at the cellular level
in vitro [24–26]. Elevated levels of free fatty acids are thought
to be a critical factor of liver diseases such as nonalcoholic
liver diseases and hepatic steatosis in obese individuals
[27, 28]. Therefore, in this study, we used free fatty acids
to induce hepatic steatosis in HepG2 cells to analyze the
beneficial effects of LAB TCF in vitro. Cells incubated with
free fatty acids showed increased accumulation of lipids
that was reduced when cells were treated with the TCF
of LAB strains. A significant decrease in lipid levels was
observed in response to treatment with 50μl of LAB TCF.
Among the LABs, the TCF of LPL exhibited better activity
than other strains, suggesting that the reduction of lipids by
the TCF of LABs is probably because of attenuation of lipo-
genesis and stimulation of lipolysis and oxidation [29, 30].
We next analyzed whether the TCF of LABs attenuated
LPS-induced inflammatory activity in HepG2 cells. Lipo-
polysaccharide is a known inducer of inflammatory response
in different cell types, including HepG2 cells [25]. Treatment
of cells with LPS induced the expression of exaggerated
proinflammatory cytokines such as IL-6, IL-1, TGF-β, and
TNF-α in vitro [24, 31]. The production of these cytokines
has been shown to play critical roles in the pathogenesis of
liver inflammation and liver damage. Ewaschuk et al. [19]
reported that mice injected with LPS/GalN showed signifi-
cant liver injury as a result of increasing permeability of the
intestine and gut bacterial translocation, as well as upregula-
tion of the production of proinflammatory cytokines in vivo.
Probiotics are promising candidates for the maintenance
of human health that are able to prevent intestinal damage
and reduce liver inflammation and injury [32, 33]. Oral
gavages of probiotics (VSL#3) have been shown to prevent
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Figure 7: Modulation of TLR-negative regulator expressions by TCF of LABs in HepG2 cells not treated with free fatty acid (normal cells).
HepG2 cells were prestimulated with total cellular fluid of LABs and poststimulated with LPS for 3 h and 12 h. The expressions of A20,
SIGIRR, Tollip, and IRAK-M1 were determined by RT-PCR. HepG2 cell treated with LPS was used as control. Different superscript letters
indicate significant differences at the 0.05 level.
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translocation of gut bacteria and liver injury in a sepsis
mouse model via peroxisome proliferator-activated receptor
gamma- (PPARγ-) dependent mechanisms [19]. Another
study of a mouse model showed that probiotic L. rhamnosus
GG administration attenuated hepatic steatosis and liver
injury through maintenance of gut barrier functions and bal-
ance of the proportion of Th17 and Treg cell populations [34].
In addition, mice fed with probiotic MIYAIRI 588 decreased
the deposition of hepatic fibrosis as well as the development
of hepatocarcinogenesis and GST-P-positive foci by increas-
ing the activation of adenosine 5-monophosphate-activated
protein kinase (AMPK), protein kinase B (PKB), and the
expression of lipogenesis-related proteins [17]. These studies
confirmed the beneficial effects of probiotics against liver dis-
eases; however, the results varied depending on strain type
and quantity [35]. Therefore, in this study, we used hepatoma
HepG2 cells to screen potent probiotic strains with immuno-
modulatory activity for human health. Our results showed
that LPS was able to induce the production of proinflamma-
tory cytokines such as IL-6, IL-8, MCP-1, and TNF-α in
HepG2 cells. Similarly, Kang et al. [25] reported that treat-
ment of HepG2 cells with LPS led to significantly upregulated
IL-1β, IL-6, and TNF-α expressions. Cells stimulated with the
TCF of LAB strains showed diminished LPS-induced proin-
flammatory cytokine expression in a time-dependentmanner.
At 3 h, the TCF of WCI and LPL significantly reduced the
expression of IL-6, IL-8, MCP-1, and TNF-α, whereas the
TCF of LSA failed to reduce the expression of IL-8 and
MCP-1 in FFA-treated HepG2 cells. At 12 h, the mRNA level
of IL-6 was reduced by the TCF of all LABs in FFA-treated
cells, but the TCF of LSA did not induce a reduction in the
levels of TNF-α in FFA-treated cells. Conversely, stimulation
of FFA-untreated cells with the TCF of LABs exhibited
different inhibition profiles than FFA-treated cells. Probi-
otic (VSL#3) administration reduced the level of hepatic
IL-6 but had no effect on the level of hepatic TNF-α in
a mouse model of sepsis [19]. IL-6 is a key inflammatory
mediator of sepsis that may alter intestinal barrier function
by increasing expression of the keratin gene in intestinal
epithelial cells [36].
TNF-α is a critical proinflammatory mediator of inflam-
mation and host immune response. Elevated levels of TNF-α
play several crucial roles in the development of liver diseases
through the upregulation of proinflammatory cytokines and
the expression of lipid metabolic and fibrogenesis markers
in the livers of mice [37]. TNF knockout reduced the progres-
sion of hepatic steatosis and fibrosis by downregulation of
MCP-1, TGF-1β, Col1a1, and TIMP-1 in transgenic mice.
Additionally, increases in the level of TNF-α were observed
in the blood circulation and liver tissues of hepatic steatosis
patients, which indicate that it is closely associated with
disease severity and morbidity [38]. Anti-TNF-α antibody
administration attenuated hepatic insulin resistance and
progression of hepatic steatosis in a mouse model [21].
Therefore, we next analyzed whether the TCF of LABs
reduces LPS-induced TNF-α production at the protein level
in vitro. Stimulation of THP-1 cells with LPS increased the
production of TNF-α, which was dampened by LAB treat-
ment. The LAB LSA exhibited significantly higher reduction
than other LAB strains. In addition, pretreatment of LABs
upregulated the expression of IL-10 in THP-1 cells, but
downregulated the level of TGF-β. IL-10 is a well-known
anti-inflammatory cytokine that plays crucial roles in improv-
ing host immune response against pathogenic invaders and
preventing inflammatory and autoimmune diseases [39].
IL-10 deficiency increased the development of chronic entero-
colitis and inflammatory bowel disease in mice [40, 41] and
has also been shown to protect hepatic injury in mice induced
by LPS and concanavalin A. Treatment with anti-IL-10 anti-
body increased the severity of hepatitis and IL-12, IFN-γ,
and TNF-α in the serum of mice [42].
Conversely, Smad-independent TGF-β signaling differ-
entially induced the progression of hepatocellular carcinoma
[43]. Administration of VSL#3 probiotics inhibited TGF-β
signaling and its expression in mice, leading to reduced
progression of MCD-induced liver fibrosis in vivo [44]. In
addition, LPS treatment induced the mRNA level of IL-6,
which was reduced when THP-1 cells were pretreated with
all LABs except LSA. Similarly, the level of IL-1β was also
diminished by all LABs, but not by LPL in THP-1 cells. Fur-
thermore, LAB stimulation did not alter the level of TLR2,
whereas it upregulated TLR4 expression in THP-1 cells.
TLR4/LPS signaling has been reported to induce activation
of MAPKs and NF-κB pathways, both of which play vital
and important roles in the regulation of several cellular
physiological processes and host immune functions [45].
Upon recognition of LPS, TLR4 activates these pathways,
which induces exacerbated forms of inflammatory states
in host cells by increasing the production of proinflamma-
tory cytokines: IL-6, IL-8, IL-1β, CXCL2, TNF-α, and
others [45]. The results of our study showed that the TCFs
of LABs were able to decrease the phosphorylation of p38
MAPK and p65 NF-κB in HepG2 cells.
TLR4/LPS signaling is known to induce exacerbation of
proinflammatory response; therefore, regulatory pathways
are needed to prevent TLR4-induced inflammatory damage
in the host. TLR4/LPS signaling can be regulated at different
levels that may from a receptor level to transcription level via
mechanisms such as deubiquitination, proteolytic degrada-
tion, and competition [46]. Some proteins have been shown
to regulate the pathway of TLR4 signaling [47], and the
expression of such regulatory proteins has been induced
by TLR4 activation, with their increased production lead-
ing to the termination of the activation of TLR4 through
negative feedback mechanisms [46]. Therefore, we investi-
gated whether the TCFs of LABs modulate the expression
of TLR-negative regulatory proteins in HepG2 cells. The
results of our study showed that the TCFs of LABs were
able to regulate the LPS-mediated activation of TLR sig-
naling by modulating the expression of TLR-negative reg-
ulators such as A20, SIGIRR, Tollip, and IRAKM in
HepG2 cells. The TCF of LABs diminished the expression
of A20 in FFA-treated cells, whereas it upregulated Tollip,
SIGIRR, and IRAKM expression in FFA-untreated cells.
SIGIRR is a cell receptor that can control the activation of
TLR4 signaling, and its deficiency in mice is more susceptible
to LPS-induced inflammatory response [48]. IRAKM is
another kind of regulatory protein that inhibits TLR4
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signaling by preventing the separation of IRAKs from
MyD88 protein [46]. Mice lacking IRAKM showed increased
expression of inflammatory cytokines/chemokines in
response to TLR4 ligands [49]. Overall, the results of this
study indicated that the TCFs of LABs were able to attenuate
LPS-induced inflammatory responses in vitro; however, this
study has some limitations. The analysis of additional
MAPKs and NF-κB proteins and in vivo study helps confirm-
ing the beneficial activity of these selected strains and better
understanding of molecular mechanisms behind the patho-
genic and beneficial role of LPS and probiotics.
5. Conclusion
This study shows the immunoregulatory potential of LAB
strains against bacterial LPS-induced inflammatory response
in vitro. The TCFs of LABs were able to suppress HepG2 cells
to produce higher levels of inflammatory cytokines such as
IL-6, IL-8, MCP-1, and TNF-α in response to LPS. LABs
achieved these beneficial effects through the modulation of
TLR-negative regulators such as A20, Tollip, SIGIRR, and
IRAKM, as well as the inhibition of MAPK and NF-κB acti-
vation. Moreover, the TCF of LABs indirectly reduced the
expression of inflammatory and anti-inflammatory cytokines
in THP-1 cells. These results suggest that the TCF of LABs
can attenuate inflammatory responses induced by LPS
in vitro; however, a further in vivo study is needed to confirm
their beneficial activity.
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